AstraZeneca’s Baxfendy approved in the USA

The US Food and Drug Administration (FDA) has approved AstraZeneca’s (LSE: AZN) Baxfendy (baxdrostat) as a first-in-class aldosterone synthase inhibitor (ASI) for the treatment of hypertension in combination with other antihypertensive medications, to lower blood pressure in adults who are not adequately controlled.

There are 1.4 billion people worldwide living with hypertension. In the US,A approximately 50% of patients living with hypertension who are already taking multiple antihypertensive medications still struggle with persistently elevated blood pressure, which is a leading risk factor for cardiovascular disease and premature death. Hypertension is the most prevalent and significant modifiable cardiovascular risk factor worldwide, accounting for more deaths and disability than any other modifiable risk.